Exelixis Inc

EXELNASDAQ · USD
66.32USD-1.97 (-2.89%)
7810

Exelixis Inc (EXEL) Covered Calls

Exelixis Inc trades in the Biotechnology industry with an IV Rank of 17.86%, low versus the past year. EXEL's highest covered call setup is the $70.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 4.32% out of the money with 4 days to expiration, a 4.47% return until expiration, and a 407.97% theoretical annualized return. Across the setups shown, annualized returns run from 54.10% to 407.97% at strikes between $67.50 and $95.00, with 4 to 186 days to expiration, as of Nov 16, 2026.

Read more

Running EXEL covered calls helps you generate income from Exelixis Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best EXEL covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If EXEL stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling EXEL covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given EXEL covered call is worth writing.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.

2026-11-20470.004.320.100.55300.004.47407.97-0.15+0.191,3630.45
2027-02-199595.0041.580.252.102815.0041.95161.19-0.37+0.1421.85
2026-12-183272.508.050.351.70575.008.5797.74-0.52+0.262391.35
2027-02-199580.0019.230.253.801315.0019.6075.30-0.37+0.26103.55
2026-11-20467.500.600.151.5055.000.8274.80-0.22+0.455251.35
2027-01-156075.0011.770.153.20805.0012.0072.98-0.22+0.283443.05
2027-05-2118690.0034.130.702.852360.0035.1769.02-1.04+0.201012.15
2027-02-199577.5015.500.854.401125.0016.7764.42-1.27+0.3103.55
2026-12-183270.004.320.402.55330.004.9256.10-0.60+0.361982.15
2027-05-2118685.0026.680.604.201850.0027.5754.10-0.89+0.25173.60

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank17.86% Low
  • Market cap (M$)16,664
  • 52 weeks high-7.33%
  • 52 weeks low71.97%
  • Analyst recommendationBuy
    2.44
  • Target price$62.08
    -6.39% below the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-09
  • P/E20.44
  • Future P/E16.07
  • EPS (ttm)3.34
  • EPS growth next 5 years19.51%

As of Nov 18, 2026